<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01379001</url>
  </required_header>
  <id_info>
    <org_study_id>K23AG031320</org_study_id>
    <nct_id>NCT01379001</nct_id>
  </id_info>
  <brief_title>Assessment of Cholinergic and Cognitive Function Using Pharmacologic ASL-Perfusion MRI</brief_title>
  <official_title>Assessment of Cholinergic and Cognitive Function Using Pharmacologic ASL-Perfusion MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebrew SeniorLife</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebrew SeniorLife</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study will look at how medications affect the pattern of blood flow in the&#xD;
      brain. This study will use a special type of MRI (magnetic resonance imaging) scan called&#xD;
      perfusion MRI to make measurements of cerebral (brain) blood flow. The medications we will&#xD;
      use in this study are scopolamine (commonly used to treat motion sickness), mecamylamine&#xD;
      (used to treat high blood pressure), and donepezil (used to treat memory loss). Cognitive&#xD;
      testing will also be obtained, and correlated with the blood flow patterns in the brain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Project Summary: This research project will investigate the value of combined pharmacologic&#xD;
      manipulation and arterial spin-labeled perfusion MRI (pharmacologic ASL-pMRI) as an in vivo&#xD;
      probe of cholinergic function. Methods to investigate cholinergic function in vivo are needed&#xD;
      to better understand the role of acetylcholine in the physiology of the cerebral cortex, and&#xD;
      in cognitive processes in health and in disease states. In this study, pharmacologic ASL-pMRI&#xD;
      will be used to characterize the normal cerebral perfusion response to cholinergic&#xD;
      manipulation in young healthy subjects. Cognitive measures will also be obtained and&#xD;
      correlated with cerebral perfusion changes. Pharmacologic ASL-pMRI and cognitive testing will&#xD;
      then be used to study how the cholinergic response is altered with normal aging and in&#xD;
      delirium&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebral blood flow</measure>
    <time_frame>3 hours</time_frame>
    <description>cerebral blood flow will be measured 3 hours after drug administration using Arterial spin-labeled perfusion MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cognitive performance</measure>
    <time_frame>4 hours</time_frame>
    <description>participants will undergo cognitive testing following drug administration and MRI acquisition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Cholinergic Function</condition>
  <arm_group>
    <arm_group_label>Young</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Young healthy controls, aged 21-35</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Older</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Older healthy controls, aged 65-80</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scopolamine</intervention_name>
    <description>Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)</description>
    <arm_group_label>Older</arm_group_label>
    <arm_group_label>Young</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IM or PO placebo</description>
    <arm_group_label>Older</arm_group_label>
    <arm_group_label>Young</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>donepezil 5mg PO x 1</description>
    <arm_group_label>Older</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy volunteers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any neurological condition, such as brain tumor, history of stroke, seizure disorder,&#xD;
             attention deficit disorder, normal pressure hydrocephalus, dementia, traumatic brain&#xD;
             injury&#xD;
&#xD;
          -  Any major medical conditions, such a cancer, diabetes, glaucoma, prostate disease,&#xD;
             uncontrolled hypertension&#xD;
&#xD;
          -  antihistamine use&#xD;
&#xD;
          -  tricyclic antidepressant use&#xD;
&#xD;
          -  presence of metal in body, including pacemaker, defibrillator, neurostimulator, metal&#xD;
             implants, or foreign metal objects such as bullets or shrapnel.&#xD;
&#xD;
          -  anxiety or panic disorder&#xD;
&#xD;
          -  history of claustrophobia&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamara Fong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hebrew Rehabilitation Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>June 21, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2011</study_first_posted>
  <last_update_submitted>January 3, 2013</last_update_submitted>
  <last_update_submitted_qc>January 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebrew SeniorLife</investigator_affiliation>
    <investigator_full_name>Tamara Fong</investigator_full_name>
    <investigator_title>Assistant Scientist/Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>cholinergic function</keyword>
  <keyword>aging</keyword>
  <keyword>pharmacologic MRI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scopolamine</mesh_term>
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

